SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

PureTech Health plc PTCHF OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

PureTech Health plc (PTCHF) is a Biotechnology company in the Healthcare sector, currently trading at $1.80. It has a SharesGrow Score of 74/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $4M, +3.3%/yr average growth. Net income is $54M, growing at +48.4%/yr. Net profit margin is 1240.1% (strong). Gross margin is 100% (+1107 pp trend).

Balance sheet: total debt is $22M against $415M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 9.33 (strong liquidity). Debt-to-assets is 3.7%. Total assets: $603M.

Analyst outlook: 2 / 2 analysts rate PTCHF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 73/100 (Pass), Past 25/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 100/100 (Pass).

PTCHF SharesGrow Score Overview

74/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 73/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 100/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PTCHF

PTCHF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

PTCHF: +3.3%/yr revenue is, +48.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

PTCHF: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet PTCHF: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 9.33 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

PTCHF: Gross margin is 100% (+1107 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 2 analysts rate PTCHF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

PTCHF: Net profit margin is 1240.1%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1.27-1.9

Volume500

Avg Volume (30D)10.56K

Market Cap$438.15M

Beta (1Y)0.69

Share Statistics

EPS (TTM)2.00

Shares Outstanding$26.97M

IPO Date2015-07-29

Employees80

CEORobert Lyne

Financial Highlights & Ratios

Revenue (TTM)$4.32M

Gross Profit$4.32M

EBITDA$37.38M

Net Income$53.51M

Operating Income$-136.1M

Total Cash$367.31M

Total Debt$22.36M

Net Debt$-258.28M

Total Assets$602.64M

Price / Earnings (P/E)0.9

Price / Sales (P/S)101.54

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINGB00BY2Z0H74

Price Chart

PTCHF

PureTech Health plc ↗ · Other OTC

Healthcare • Biotechnology

1.27 52WK RANGE 1.90

People Also View

Karuna Therapeutics, Inc.

Blueprint Medicines Corporation

Cerevel Therapeutics Holdings, Inc.

IVERIC bio, Inc.

Apellis Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message